Abstract 375P
Background
To determined survival and prognostic factors for non-nasopharyngeal head and neck squamous cell carcinoma (HNSCC) patients treated with surgery followed by concurrent chemoradiotherapy (CCRT) or definitive CCRT (dCCRT), aiming to identify optimal chemotherapy doses.
Methods
This retrospective cohort study reviewed 277 non-NPC HNSCC patients treated with platinum-based CCRT at Rajavithi Hospital between January 1st, 2016 and April 30th, 2021. Clinical features, staging, treatment, and outcomes were collected and analyzed.
Results
Overall, 277 patients were diagnosed as HNSCC; median age: 55.9 years; male: 81.2%; ECOG 0-1: 98.9%. The clinical stage was I-III, IVa, and IVb in 23.8%, 53.4%, and 22.8%, respectively. Cisplatin was used in 39.0%, while carboplatin was used in 61.0%. 53.4% underwent surgery followed by CCRT while 46.6% underwent definitive CCRT. Patients treated with adjuvant CCRT led to significantly longer overall survival (OS) and disease-free survival (DFS) than definitive CCRT (HR: 0.54, p<0.001 for OS; HR: 0.61, p<0.001 for DFS). Higher stage and the presence of pathological risk factors were poor prognostic factors for OS in the adjuvant CCRT group, while higher stage and oral cavity and hypopharynx were associated with poorer OS in the definitive CCRT group. Among the interquartile range of cumulative doses (CDs), the study also found a statistically significant difference in OS and DFS for the dCCRT group with carboplatin at the 2nd Quartile compared to the others (6.75-8.58 AUC) (HR 0.38, 95%CI; 0.17-0.86, p=0.02 and HR 0.41, 95%CI; 0.18-0.91, p=0.03, respectively). There was no significant difference in OS/DFS between patients who received CDs of cisplatin of either less or more than 200 mg/m2 or carboplatin in adjuvant CCRT in all population.
Conclusions
This study showed comparable survival outcomes to historical data. Surgery followed by adjuvant CCRT remains the recommended approach. The CDs of cisplatin or carboplatin did not significantly impact outcomes. A trend towards improved survival with CDs within a specific range requires confirmation in further prospective studies.
Clinical trial identification
6518.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract
310P - A study on the prediction of recurrence site of endometrial cancer using various machine learning techniques
Presenter: Wonkyo Shin
Session: Poster Display
Resources:
Abstract
311P - Circulating cytokines in the differential diagnosis of endometrial cancer
Presenter: Tatyana Abakumova
Session: Poster Display
Resources:
Abstract
312P - Molecular and genetic features of squamous cell carcinoma of vulvar cancer depending on HPV status
Presenter: Visola Navruzova
Session: Poster Display
Resources:
Abstract
313P - Efficacy and safety of oral metronomic chemotherapy in recurrent refractory advanced gynaecological cancer: Experience from regional cancer center of eastern India
Presenter: Ranti Ghosh
Session: Poster Display
Resources:
Abstract
314P - Perioperative outcomes in advanced epithelial ovarian cancer treated with neoadjuvant bevacizumab and chemotherapy: Real-world experience from an Indian cancer centre
Presenter: Upasana Palo
Session: Poster Display
Resources:
Abstract
315P - Real-world experience of niraparib as maintenance therapy in newly diagnosed advanced ovarian cancer: A single-center retrospective study
Presenter: Wenxin Liu
Session: Poster Display
Resources:
Abstract
316P - First evidence of olaparib maintenance therapy in patients with newly diagnosed BRCA wild-type ovarian cancer: A real-world multicenter study
Presenter: Jing Li
Session: Poster Display
Resources:
Abstract
317P - Attitudes of Israeli gynecologists towards risk reduction salpingo-oophorectomy at hysterectomy for benign conditions and the use of hormonal therapy
Presenter: wisam Assaf
Session: Poster Display
Resources:
Abstract
319P - Survival prediction for ovarian cancer patients from Taiwan cancer registry data
Presenter: Tzu-Pin Lu
Session: Poster Display
Resources:
Abstract